Tomas Simunek
Overview
Explore the profile of Tomas Simunek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerestes V, Kubes J, Applova L, Kollarova P, Lencova-Popelova O, Melnikova I, et al.
Toxicol Sci
. 2024 Jan;
198(2):288-302.
PMID: 38290791
Anthracyclines, such as doxorubicin (adriamycin), daunorubicin, or epirubicin, rank among the most effective agents in classical anticancer chemotherapy. However, cardiotoxicity remains the main limitation of their clinical use. Topoisomerase IIβ...
2.
Incocciati A, Kubes J, Piacentini R, Cappelletti C, Botta S, Bertuccini L, et al.
Protein Sci
. 2023 Oct;
32(12):e4819.
PMID: 37883077
Ferritin, a naturally occurring iron storage protein, has gained significant attention as a drug delivery platform due to its inherent biocompatibility and capacity to encapsulate therapeutic agents. In this study,...
3.
Haskova P, Applova L, Jansova H, Homola P, Franz K, Vavrova K, et al.
Sci Rep
. 2022 Jun;
12(1):9765.
PMID: 35697900
Labile redox-active iron ions have been implicated in various neurodegenerative disorders, including the Parkinson's disease (PD). Iron chelation has been successfully used in clinical practice to manage iron overload in...
4.
Pokorna Z, Kollarova-Brazdova P, Lencova-Popelova O, Jirkovsky E, Kubes J, Mazurova Y, et al.
Clin Sci (Lond)
. 2021 Dec;
136(1):139-161.
PMID: 34878093
Angiotensin-converting enzyme inhibitors (ACEis) have been used to treat anthracycline (ANT)-induced cardiac dysfunction, and they appear beneficial for secondary prevention in high-risk patients. However, it remains unclear whether they truly...
5.
Jirkovsky E, Jirkovska A, Bavlovic-Piskackova H, Skalicka V, Pokorna Z, Karabanovich G, et al.
Circ Heart Fail
. 2021 Sep;
14(11):e008209.
PMID: 34551586
Background: Anthracycline-induced heart failure has been traditionally attributed to direct iron-catalyzed oxidative damage. Dexrazoxane (DEX)-the only drug approved for its prevention-has been believed to protect the heart via its iron-chelating...
6.
Kollarova-Brazdova P, Lencova-Popelova O, Karabanovich G, Kocurova-Lengvarska J, Kubes J, Vanova N, et al.
Clin Sci (Lond)
. 2021 Jul;
135(15):1897-1914.
PMID: 34318878
The anthracycline (ANT) anticancer drugs such as doxorubicin or daunorubicin (DAU) can cause serious myocardial injury and chronic cardiac dysfunction in cancer survivors. A bisdioxopiperazine agent dexrazoxane (DEX) has been...
7.
Jirkovska A, Karabanovich G, Kubes J, Skalicka V, Melnikova I, Korabecny J, et al.
J Med Chem
. 2021 Mar;
64(7):3997-4019.
PMID: 33750129
Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved drug against anthracycline-induced cardiotoxicity, has traditionally been attributed to its iron-chelating metabolite. However, recent experimental evidence suggested that the inhibition and/or...
8.
Bavlovic Piskackova H, Jansova H, Kubes J, Karabanovich G, Vanova N, Kollarova-Brazdova P, et al.
Sci Rep
. 2021 Feb;
11(1):4456.
PMID: 33627707
The bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 has been previously identified as a more potent analog of dexrazoxane (ICRF-187), a drug used in clinical practice against anthracycline cardiotoxicity. However, the poor...
9.
Kollarova-Brazdova P, Jirkovska A, Karabanovich G, Pokorna Z, Bavlovic Piskackova H, Jirkovsky E, et al.
J Pharmacol Exp Ther
. 2020 Apr;
373(3):402-415.
PMID: 32253261
Bisdioxopiperazine agent dexrazoxane (ICRF-187) has been the only effective and approved drug for prevention of chronic anthracycline cardiotoxicity. However, the structure-activity relationships (SARs) of its cardioprotective effects remain obscure owing...
10.
Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, et al.
Clin Sci (Lond)
. 2019 Aug;
133(16):1827-1844.
PMID: 31409729
Although proteasome inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines...